Insights Into the Management of Lower-Risk Myelodysplastic Syndromes (LR-MDS) 2024
Perspectives of community physicians from across the US on current practices in the management of LR-MDS
California – October 12, 2024
Faculty Chair
Danko Martincic, MD
Beacon Clinic, Coeur d'Alene, ID, USA
More Information
- San Diego, CA
- California, Wisconsin, Illinois, Massachusetts, Missouri, Tennessee
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on physicians’ experience with luspatercept in LR-MDS, including patient characteristics, management of cytopenias, and barriers to use
- Disease state and data presentations were developed in conjunction with a national or regional oncology expert
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region
